- Home
- Â /Â Delcath Systems
Delcath Systems
Stock Price
$10.4
2024-10-29
Market Capitalization
$294.6 M
2024-10-29
Revenue
$2.1 M
FY, 2023
Delcath Systems Summary
Company Summary
- Overview
- Delcath Systems is an interventional oncology company which focuses on the treatment of primary and metastatic liver cancers. The Company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver.Â
- Type
- Public
- Status
- Active
- Founded
- 1988
- HQ
- New York, NY, US | view all locations
- Website
- http://www.delcath.com
- Cybersecurity rating
Table of Contents
Key People
Bridget Martell, Director
Martha S. Rook, Chief Operating Officer
Johnny John, SVP, Clinical Operations and Medical Affairs
LocationsView all
3 locations detected
New York, NYÂ HQ
United States
Paramount Plaza, 1633 Broadway 22nd Floor, Suite C
Queensbury, NY
United States
566 Queensbury Ave
Galway
Ireland
Unit 19 Mervue Business Park
Delcath Systems Financials
Summary Financials
- Revenue (Q3, 2024)
- $11.2M
- Gross profit (Q3, 2024)
- $9.6M
- Net income (Q3, 2024)
- $1.9M
- Cash (Q3, 2024)
- $8.3M
- EBIT (Q3, 2024)
- ($1.3M)
- Enterprise value
- $289.1M